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Summary: A new class of deep eutectic solvents are presented where one component is inherently 
volatile, enabling a premeditated, auto-destructive capability which can lead inexorably to novel 
crystal structures. These deep eutomic solvents are easily-formed liquids with a greatly depressed 
melting point and exhibit all of the physical characteristics of classical deep eutectic solvents, with 
the exception that one of the components is volatile when exposed to the atmosphere at room 
temperature. We demonstrate the effectiveness of this concept through the controlled 
crystallisation of pharmaceuticals, among which is a more efficacious, yet hard to reach form of 
paracetamol, which can now be formed spontaneously for the first time at room temperature. 
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Born from the class of solvents known as ionic liquids, the deep eutectic solvents (DES), named 
from the Greek “εu” (eu = easy) and “τήξις” (teksis = melting), have been an increasingly well-
researched class of solvents for the last two decades. They have been a boon to catalysis, extraction 
processes, electrochemistry, organic synthesis and in the creation of more efficient batteries and 
dye-sensitized solar cells1-7. Originally conceived as a greener and cheaper alternative to the more 
toxic and less environmentally-friendly ionic liquids8,9, DES are normally composed of two or 
three molecular species which are able to associate through extensive hydrogen bonding10. The 
judicious admixture of two solid crystalline components forms a liquid with a melting point 
significantly lower than each of the constituents giving rise to their ubiquity. One of the first 
examples of a deep eutectic solvent was formed by the mixture of solid choline chloride and urea 
in a molar ratio of 1:2. This eutectic mixture is a liquid at 12 °C, whilst the component parts have 
melting points of 302 °C and 133 °C respectively. Although the first DES were formed by the 
mixing of a quaternary ammonium salt with a hydrogen bond donor (HBD)11, a number of suitable 
alternative formulations have subsequently been conceived, the majority utilising an amide moiety 
as a hydrogen bond acceptor (HBA). DES are being exploited within the pharmaceutical industry 
to tackle two of the industry’s biggest issues: polymorphic control and poor solubility. Currently, 
more than 50% of active pharmaceutical ingredients (APIs) are known to exhibit polymorphism 
and up to 90% of new chemical entities considered for bringing to market are classed as poorly 
soluble12. DES have been explored both as a vector for enhancing the solubility of an API and the 
incorporation of an API as one of the eutectic components, forming “therapeutic DES” 13-16, 
although the bioavailability of APIs delivered in this form has been shown to be lower than 
standard oral solids. 
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When developing an API, one of the primary considerations for bringing a new chemical 
entity to market is polymorphic stability. A sudden change in polymorphic form can result in 
radical changes to intermolecular interactions and the crystal surface chemistry which can 
detrimentally affect solubility, dissolution rate and intestinal permeability17. On a larger scale, 
different polymorphs often have different crystal habits which can have a significant impact on the 
processability of the API. Greater cohesion between crystals from the increased amount of exposed 
polar surfaces, leads to clogging of processing hardware. Typically, additional mechanical 
processes such as milling are used to reduce particle size. However, milling is accompanied by 
concerns over mechanically induced solid-state transformations of the API and agglomeration of 
the produced particles18,19. For these reasons, identification of new polymorphs alongside control 
over polymorphism, crystal habit and micromorphology remain major resource sinks within the 
pharma industry. The socioeconomic and research impact of directing crystal growth in 
pharmaceutical compounds cannot be overstated; existing, drugs which have no scalable route to 
a form with a desirable crystal habit can freeze in development, as can APIs that are not easily 
processable into tablets with a suitable dissolution profile. Unfortunately, the most 
thermodynamically stable polymorph of an API is the least soluble when compared to higher 
energy metastable forms. However, these higher energy polymorphs often require relative 
extremes of crystallisation conditions or complex synthetic routes such as desolvation or epitaxial 
growth to isolate. This is the case with one of the most widely produced APIs, paracetamol20, 
which has three known polymorphs, form I, II and III, named in order of discovery. Paracetamol 
is manufactured and distributed as form I, a less efficacious form, due to its ease of production and 
crystalline stability. Form II is more soluble and is more readily compressed into tablets, however 
it is more difficult to crystallise, requiring additives or extremes of temperature. Using existing 
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methods, obtaining higher energy, more efficacious polymorphs of any API is not a cost-effective 
strategy when having to scale up and therefore what is required is a simple method of API 
crystallisation and polymorph control which is scalable and works at room temperature and 
pressure. 
Here we introduce a new class of deep eutectic solvent which, through spontaneous and 
catastrophic reversal of the eutectic liquidation, affords the potential for (i) polymorphic control, 
(ii) macromorphological control (iii) the creation of a solvate of an API, depending on the API’s 
molecular structure. This concept of a self-destructing deep eutectic solvent has not been 
previously explored. We christen this new class a ‘Deep Eutomic Solvent’ (DXS), named from the 
Greek “εu” (eu = easy) and “τομή” (tomi = cutting), and show their efficacy by creating APIs via 
a liquid-based method which is scalable and works at room temperature and pressure. Furthermore, 
we discuss the molecular features of the API that give rise to either polymorph control, 
macromorphological control or solvate formation and suggest general features that should make 
our method applicable to the controlled crystallisation of all small organic molecules. 
Deep Eutomic Solvent synthesis and polymorphic control in benzamides 
The DXS system comprises a volatile HBD and stable HBA component in the ratios 1:1-10:1 
(HBD:HBA) which, when simply mixed together as solids, produces a liquid which remains stable 
in a sealed container at or near room temperature. In this work, we use a pharmaceutical as the 
HBA component, which means that a liquid is produced containing the pharmaceutical at 
extremely high concentrations. Once completely liquid, droplets of the DXS were left under 
ambient conditions for the HBD to evaporate resulting in destruction of the DXS and spontaneous 
crystallisation of the pharmaceutical HBA. Subsequent NMR of solutions of the as-crystallised 
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HBA showed no detectable residual HBD present. The range of ratios at which a stable DXS is 
formed affords an easily tunable array of concentrations with regards to the API in the solvent and 
it is a feature of the DXS system that all eutomic mixtures formed exhibited deep eutectic behavior 
with melting point depressions or glass transitions significantly lower than the component parts 
ranging from ~ 29 ˚C to sub -70 ˚C (Table 1). The viability of the DXS method is demonstrated on 
a simple system consisting of phenol as the HBD and benzamide as the HBA. Phenol and 
benzamide were chosen as simple molecules containing functional groups which are typical in 
DES formation. Phenol and phenolic compounds have been widely explored as the hydrogen bond 
donating component in eutectic systems for both extraction processes and pharmaceutical 
applications13. Benzamide is a good model system for an API as it has a structural motif found in 
many drugs21 and currently has three known forms (forms I, II and III). The highly metastable 
form II and form III are formed concomitantly at higher supersaturations but will transform to 
form I over time. The effect of altering functional groups on the eutomic behavior was examined 
using 2-methoxybenzamide (2MB) and 2-ethoxybenzamide (2EB), as simple variations on the 
underlying benzamide structure (fig. 1). Phenol:benzamide mixtures were within the range 4:1 - 
9:1, all of which resulted in a homogeneous clear liquid at room temperature. On destruction of 
the DXS, large crystals of the form III polymorph of benzamide were produced, interspersed with 
opaque needles of form I (Supplementary Information fig. S1). This suggests that a metastable 
crystal is forming, followed by the rapid conversion to the other polymorph. Upon aging in sealed 
vials prior to HBD evaporation however, a DXS of ratio 9:1 phenol:benzamide consistently gave 
only the form III polymorph (Supplementary Information fig. S2). The lack of conversion from 
form III to form I from the aged solutions is at least suggestive that none of the more stable form 
I is present at any point during the crystallisation. We can understand this mechanistically through 
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consideration of the molecular interactions between the HBD and HBA. The capacity to form 
intermolecular hydrogen-bonding networks have been shown to be essential in DES formation, 
indeed there must be a propensity for the HBD:HBA interaction to be energetically more favorable 
than molecular self-interaction. In addition, from our data, it is clear that the introduction of steric 
effects in benzamide derivatives alter the tendency for DXS formation and destruction. These 
altered interactions can be correlated with a change in melting point as a function of increasing 
steric interactions of the HBD and HBA. The lowest recorded melting points of benzamide, 2MB 
and 2EB eutectics are found to be -37.57 °C, -38.87 °C and -37.91 °C respectively, which is also 
reflected in the speed at which these mixtures form liquids when the deep eutomic solvent is 
created (Table 1). Interestingly, 2MB is the most freely forming DXS with the lowest melting 
point, implying perhaps unsurprisingly that a balance between number and accessibility of 
hydrogen bonding sites are required when designing a DXS system (Supplementary Information 
Table S1). By using a DXS system in the crystallization of benzamides therefore, choice of crystal 
polymorph can be made by the simple ageing of the DXS of a given HBD:HBA ratio prior to 
crystallisation.  A different route to polymorph control however can be seen in the DXS system of 
paracetamol. 
Polymorph control in paracetamol 
With the knowledge that the number and propensity of HBD:HBA interactions are critical to the 
successful formation of a DXS, we were able to actively control polymorphism in paracetamol by 
varying the HBD:HBA ratio. Regioisomers of paracetamol, where the acetamide group can be on 
three possible ring positions, para-, meta- and ortho- (PAP, MAP, OAP respectively) (fig 2) were 
investigated and confirmed that molecular interactions are indeed key to the ability of a DXS to 
form and in the eventual polymorph produced on DXS destruction. Of the three polymorphs of 
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PAP, two are common; form I, the ubiquitous polymorph is based around a catemeric arrangement 
and crystallises from organic solvents whereas form II is invariably grown from the melt and is 
based on a stacked dimer. Of the two other regioisomers, MAP is considered a potential less-toxic 
alternative to PAP and has two known polymorphs. One, a catemeric orthorhombic from and the 
second, a dimer-based, monoclinic form reported recently22. OAP is the least studied of the ‘-
cetamol’ family, with no reported crystal structures or powder patterns. OAP has no current 
industrial or pharmaceutical applications but has recently shown potential as an anti-tuberculosis 
therapeutic23 and as a highly promising candidate in the treatment of arthritis24. 
As with the benzamide system, ranges of PAP, MAP and OAP were made into a homogeneous 
liquid DXSs using phenol as the HBD. PAP and MAP were found to produce a stable DXS 
between the ratios of 4:1 and 9:1 and 5:1 and 10:1 (HBD:HBA), respectively. OAP formed no 
stable deep eutectic up to a ratio of 10:1. This shows clearly that the position of the acetamide 
relative to the hydroxyl group is playing a pivotal role in how the DXS forms. When in the para 
position there are a wider range of angles available for the phenol to approach and hydrogen-bond 
with the API, enabling the formation of a stable DXS at lower HBD:HBA ratios. In contrast to 
this, when in the ortho position in OAP, the proximity of the hydroxyl group to the amine prohibits 
hydrogen bonding around the molecule in numbers sufficient to make a stable liquid. DXS systems 
created from PAP and MAP however are so easily formed that they allow crystals to be grown 
from a solution with API concentrations inaccessible by many common organic solvents (fig. 3). 
We demonstrate that in the case of PAP, the most efficacious polymorph (form II) currently 
considered commercially unsuitable for production due to difficulties discussed above, will 
emerge from a DXS spontaneously at room temperature and pressure, without the addition of any 
additives, templates or epitaxial constraints (Supplementary Information fig. S3). Evaporation of 
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the volatile phenol component from all HBD:HBA ratios, leads to the formation of PAP 
polymorphs over a 10-day period. Analysis of resultant crystals from phenol:PAP ratios from 4:1 
- 9:1 show a stark difference in crystal habit, with a change from one morphology to the other, 
usually between the ratios 6:1 and 7:1.  Powder X-ray diffraction analysis shows that this 
difference is due to a different polymorph being formed, namely form I (4:1 - 6:1) and form II (7:1 
- 9:1) of which the crystal habit observed is characteristic; diamonds in the case of form I and 
needles in form II (fig. 4 and Supplementary Information fig. S4). As can be seen, with a ratio of 
4:1 phenol:PAP, a mixture of polymorphs are observed although most commonly the PAP 
polymorph that crystallises is form I. When the ratio is increased to 5:1 and 6:1, exclusively form 
I is observed over the course of ten days, in contrast to ratios of 7:1 – 9:1, which are dominated by 
form II.  The selection of form I or form II paracetamol as a simple function of a change in DXS 
composition at room temperature is a completely reproducible and non-stochastic method of 
polymorph control.  We describe the mechanism underlying this control in the section below. 
MAP also appears to have a stark division between two crystalline forms depending on the DXS 
composition ratio, although in this case, it is a change in macromorphology, rather than polymorph 
that results on crystallisation.  In all experiments, only a single polymorph of MAP, form I, is 
observed (Supplementary Information fig. S5). The final regioisomer, OAP, formed no deep 
eutectic solution and so no crystals were generated. 
How polymorphism is being controlled in paracetamol 
In order to understand why there is a stark change in polymorph as a function of phenol 
concentration, molecular optimisation calculations, using the software ORIENT25, were carried 
out to look at the energetically favourable configurations of phenol molecules when taking part in 
hydrogen-bonding with PAP in both polymorphs (fig. 5). Both forms I and II of PAP contain a 
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hydrogen-bonded ring of four molecules as a structural sub-unit. The structure of the ring in form 
I contains molecules orthogonally disposed to each other (fig. 5(a)), whereas molecules in form II 
sit almost parallel to each other (fig. 5(b)). Results from the calculations show that the form I motif 
has fewer sites for phenol molecules to occupy than in the form II motif, however, they are at 
lower energies. The result of this is that the addition of extra phenol molecules will promote the 
formation of form II hydrogen-bonding motifs and therefore the appearance of the polymorph 
change at high phenol concentrations. In contrast, the crystalline motifs in MAP (fig. 6) show no 
such difference in possible phenol sites, highlighting why no polymorphic change is observed 
when changing the ratio of phenol:MAP. 
What is deeply intriguing is that there is a DXS ratio in PAP where one polymorph 
consistently forms and not the other, despite the fact that as the phenol evaporates, a DXS of higher 
concentration must presumably pass through the same phenol:API ratio as one of a lower ratio that 
gives a different polymorph.  For example, phenol:paracetamol of a ratio of 8:1 consistently 
produces form II, despite passing through an (e.g.) 5:1 ratio as the phenol evaporates, before 
crystallising. Starting with a phenol:paracetamol ratio of 5:1 however consistently produces form 
I.  This phenomenon can be understood to be indicative of the fact that for each starting ratio, the 
HBD:HBA interaction that is established from the start is likely to be subtly different from each 
other and so, from the start of the evaporation of the phenol, both systems are molecularly distinct 
and would therefore not be expected to undergo crystallisation in the same way. Each system may 
possess characteristic pre-nucleation clusters from the start, which persist until crystallisation 
occurs; indeed, such clusters are now being observed in APIs26. 
Formation of cocrystals and solvates 
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Table 1 describes a list of all APIs used as HBAs during this study. Upon attempting DXS creation 
with some of these molecules, it is clear that it is not simply a question of propensity to hydrogen-
bond which determines the eventual crystalline form. In some cases, formation of a stable novel 
cocrystal of API and phenol occurs, with the phenol effectively playing the role of ‘solvate’ in the 
crystal. These solvate structures so far, lead to known forms of the API upon desolvation of the 
crystal. In the case of harmine, a reversible monoamine oxidase inhibitor, the phenolate is a 
precursor to the only know native crystalline form. As well as harmine, 2EB has been found to 
have a stable phenol cocrystal observable during phenol evolution. Both of these novel structures 
are 1:1 HBD:HBA and have been solved by us (Supplementary Information fig. S6 - CCDC 
deposit numbers 1879689 and 1879336, respectively). Upon gentle heating or vacuum drying of 
the harmine phenolate, the macromorphology of the crystal is preserved (fig. 7(a, b)), but the large 
single-crystals have been transformed into a porous, polycrystalline matrix through loss of phenol 
(fig. 7(c)). This immediately suggests another use of DXS systems as a vector to produce higher 
surface area APIs via desolvation, a current area of particular interest in the improvement of API 
bioavailability27. With this in mind, we compared the rates of dissolution of DXS-created 
carbamazepine and metaxalone to their traditionally-crystallised standard forms. In DXS-
crystallised carbamazepine, it was found that on average 50% of the API had dissolved 24.85 mins 
after the start of the dissolution experiment compared to 1.15 mins in the standard form. A similar 
profile was seen in DXS-crystallised metaxalone, with 50% of form A and C of the API dissolving 
52.27 mins and 11.02 mins respectively, compared to 6.75 mins in the standard form 
(Supplementary Information fig. S7). 
Interactions between components in a DXS are dynamic and are facilitated by an array of 
possible bonding motifs. For example, the inception of crystallisation of a 1:1 cocrystal 
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dramatically changes the concentrations of the liquid in the system, which must lead to a change 
in the nature and number of molecular interactions throughout the whole system. This complexity 
will be manifest in systems even where no cocrystal has been detected and at ratios beyond 1:1. 
The mere fact that some cocrystals have been isolated and solved provides a likely route for the 
structural control exhibited by some of these systems, both polymorphological and morphological 
when grown out of a DXS. 
Thermal analyses of deep eutomics 
To understand the extent of melting point depression in deep eutomic solvents, DSC was 
performed on all compositions and ratios of phenol:API.  All DXS systems show large melting 
point depression for all molar ratios studied (Supplementary Information Table S1). Melting 
endotherms are broad and often occur at or just after the crystallisation exotherm leading to a ± 5 
°C uncertainty in melting point depression. Melting points in the region 0 - 15 °C are observed for 
all compositions studied of paracetamol and phenol (c.f. paracetamol form I with Tm ~169 °C).  
For MAP (Tm ~ 147 °C), melting point depression is not as marked as for PAP, with melting points 
in the range 8 - 30 °C.  Benzamide (Tm ~ 127 °C), 2MB (Tm ~ 127 °C), 2EB (Tm ~ 132 °C), two 
other APIs, Metaxalone (Tm ~ 122 °C), and Carbamazepine (Tm ~ 192° C) phenol DXS’s show 
melting onsets in the ranges -6 to 15 °C, -19 °C to 1 °C, -9 °C to 22 °C, -3 to 13 °C, and -10 to -1 
°C respectively.  Although the melting point depression within a particular system is consistent 
within a narrow temperature range, there are some differences in physical behavior.  For instance, 
phenol:MAP 3:1 does not crystallise upon cooling from ambient to -70° C but will crystallise upon 
heating at ~ -17 °C followed by a melt at ~2 °C.  For phenol:MAP 5:1, a crystallisation event is 
observed upon cooling from ambient at ~ -13 °C.  Melting is subsequently observed upon heating 
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at ~ 25 °C.  This is evidence of a more complex phase behavior in these DXS systems and is a 
topic of current investigation. 
Outlook 
In this study, we prepared a range of deep eutomic solvents as binary mixtures of an API and a 
hydrogen bond donor. The deep eutomic solvent is then left to self-destruct through diffusion of 
the more volatile component out of the system leaving the less volatile pharmaceutical to 
crystallise. As we have demonstrated, suppression of the melting point in the optimum deep 
eutomic ratio leads to a crystallisation temperature typically 40 ˚C below room temperature (60 ˚C 
below that of phenol) and often greater than 100 ˚C below room temperature. It is clear from our 
modelling of these systems that the mechanisms of crystallisation from a deep eutomic solution 
are inexorably linked to both the molecular structure of the API and the packing within the resultant 
crystals. The propensity for potential hydrogen-bonding in each system appears to be pivotal in 
determining how likely an API is to form a DXS and at what ratios before there is crystallisation 
of either the API at one extreme or the co-former at the other. This is exemplified in the case of 
PAP, MAP and OAP; as the available locations for hydrogen-bond interactions decreases, so do 
the concentrations of API in the solvent. In the benzamide system, again spontaneous formation 
of a stable liquid is fastest with 2-methoxybenzamide, where there are both a carboxamide and an 
ester moiety present, in contrast to benzamide and 2-ethoxybenzamide, whose ester is more 
sterically hindered. 
We have shown here that deep eutomic solvents are a new class of deep eutectic solvent, 
the distinction being the ability of the new system to self-destruct under ambient conditions, to 
leave a crystal of one component. Furthermore, we have demonstrated that crystal formation from 
a DXS delivers a novel route of crystallisation from liquids of APIs at high concentrations at room 
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temperature and also provides a vector for polymorph selectivity in APIs, either through a change 
in concentration, or by varying the age of the DXS before allowing it to crystallise. Also, by 
accessing intermediate solvates, it may lead to the creation of new macromorphologies, thereby 
enabling the kinetics of dissolution to be altered. 
These deep eutomic solvents have now opened the door to the possibility of controlling 
organic crystal polymorphism in a scalable way at room temperature, with the additional 
possibility of creating previously unforeseen polymorphs and solvates. The control over 
polymorphism and/or the creation of novel polymorphs and solvates in this way has immediate 
and far-reaching implications for the pharmaceutical industry, where the successful granting and 
defending of patents relies on having full knowledge of the crystallisation landscape of any given 
API. 
 
Materials and methods 
Blank FaSSIF v2 (pH 6.5) was prepared by AstraZeneca (UK). Methanol and ethanol were 
supplied by Fisher Scientific (UK). All other chemicals were purchased from Sigma Aldrich and 
used as received.  
DSC analysis was performed using a TA Instruments Q2000 with refrigerated cooling system.  
The DSC cell was purged with nitrogen. Samples were analyzed in hermetically sealed aluminum 
pans.  A small volume of liquid (~ 2-5 uL) was added to the hermetic pan and sealed.  All liquid 
 14 
 
samples were cooled from 25 °C to -70 °C and then heated to 100 °C all at 10 °C/min.  The 
instrument was calibrated using a pure indium standard. 
Novel crystal structures were solved using single crystal X-ray diffraction. Crystals were of 
sufficient size (> 0.2 x 0.2 x 0.2 mm) were isolated during DXS destruction and mounted on a 
glass fibre. Intensity data for crystal structures were collected at 100 K on a Bruker Kappa Apex 
II diffractometer, using molybdenum Kα 28 radiation (λ = 0.7136 Å). Data were processed using 
Bruker APEX2 v2.0 and Olex2 v1.2.7 software. For all structures a symmetry-related (multi-scan) 
absorption correction was applied. Structure solution followed by full-matrix least squares 
refinement was performed using the WINGXv2014.1 suite of programs throughout. Specific 
information about data collection and reflections can be found embedded in the associated cif files. 
Powder X-Ray diffraction data were acquired using a Bruker D8 Advance diffractometer with a 
PSD LynxEye Detector (Cu-Kα radiation wavelength of 1.5418 Å). Step size was 0.0171°/2θ and 
step hold time was 1.5 s. 
The dissolution experiments were performed on a µDISS Profiler™ (Model: R2D; Manufacturer: 
Pion Inc., USA) equipped with 1 mm probes (for CBZ) and 2.5 mm probes (for MTX). A Mini-
bath (Model: MB8; Manufacturer: Pion Inc., USA) was used to maintain the temperature of the 
dissolution medium at 37 °C. All samples were ground in a pestle and mortar prior to dissolution 
studies to ensure a consistent particle size. 
10 mg/mL stock solutions of commercial CBZ and commercial MTX were prepared in ethanol 
and methanol, respectively. These were used to spike by serial addition (6 x 100 μL) 50 mL of 
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Blank FaSSIF v2 (pH 6.5) so to obtain a standard curve having concentration range between 0 and 
118 μg/mL. 
Approximately 1.5 mg of each material were weighed and transferred into suitable vials. 20 mL 
of Blank FaSSIF v2 (pH 6.5) at 37 °C were added to each vial and the μDISS dissolution 
experiment was started. Teflon™ coated magnetic stirrers (cross type) were set at 250 rpm. The 
dissolution experiments were run for approximately 70-80 min. The UV spectra were collected 
and analysed using a 2nd derivative function with AuPRO™ software (Version: 5.5.3.4817; 
Manufacturer: Pion Inc., USA). The selected wavelength range for CBZ was 280-295 nm while 
that for MTX was 274-278 nm. 
Samples for NMR samples (both 1H and 13C) were prepared by dissolving 50 mg of sample in 0.7 
cm3 of deuterated solvent with a tetramethylsilane reference standard and filtered. All NMR 
measurements were carried out on a Varian 400-MR (400 MHz NMR machine). 
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Figure 1. The structures, from left to right, of benzamide, 2-methoxybenzamide and 2-ethoxybenzamide. 
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Figure 2. The three structures of acetaminophenol. From left to right: PAP, MAP and OAP. 
  
 22 
 
 
 
Figure 3. The solubility of paracetamol in different organic solvents. The grey bar represents the 
solubilities acquired by the phenol DXS before decomposition. 
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Figure 4. Crystalline identity of PAP and MAP as a function of both time and HBD:HBA ratio. (a) Red 
and blue squares indicate forms I and II of paracetamol, respectively. (b) Green and orange blocks 
indicate dendrites and fibres of metacetamol, respectively. Days indicated on the y-axis denote time since 
the DXS was created. 
  
(a) (b) 
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Figure 5. Hydrogen-bonding motifs in crystalline forms of PAP. (a) A chair-like cycle of interacting PAP 
molecules in form I. Orange arrows and taupe cornered lines indicate the angles and sterically obstructed 
approach vectors. (b) The cycle of interacting PAP molecules in form II showing a more ‘planar’ 
structure. Individual molecules are coloured for ease of visualisation. Black lines indicate hydrogen-bonds 
of lengths (a) 1 = 2.049 Å and 2 = 1.796 Å and (b) 1 = 2.118 Å and 2 = 1.835 Å. 
  
(a) (b) 
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Figure 6. Hydrogen-bonding motifs in crystalline forms of MAP. (a) Upper: Helical chain and lower: 
linear chain of interacting MAP molecules in form I. (b) Dimer of interacting MAP molecules in form II. 
Individual molecules are coloured for ease of visualisation. Black lines indicate hydrogen-bonds of 
lengths (a) 1 = 2.080 Å and 2 = 1.819 Å and (b) 1 = 1.849 Å and 2 = 1.837 Å. 
  
(a) (b) 
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Figure 7. Different crystalline forms of harmine. (a) Optical image of crystals of harmine phenolate and 
(b) an optical image of same crystals after vacuum drying to remove the phenol leaving the standard 
harmine crystal structure. (c) SEM micrograph of the surface of the dried harmine in (b) revealing a 
porous micromorphology with an average pore size of 0.22 μm. 
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API HBD Min* Max* 
HBA Mp† 
(˚C) 
Lowest 
recorded 
Mp (˚C) 
Polymorph 
selectivity? 
Crystal 
habit 
selectivity? 
Carbamazepine Phenol 2:1 10:1 192 < -70 Y N 
Paracetamol Phenol 4:1 10:1 169 -32.58 Y N 
Metacetamol Phenol 2:1 10:1 147 -15.05 N Y 
Orthocetamol Phenol 10:1 10:1 205-210 - - - 
Ibuprofen Phenol 1:1 10:1 76 -23.98 N Y 
Tadalafil Phenol 6:1 10:1 301 -20.99 N Y 
Metaxalone Phenol 3:1 10:1 122 -31.84 Y N 
Benzamide Phenol 4:1 10:1 127 -37.57 Y N 
2-Methoxybenzamide Phenol 4:1 10:1 127 -38.87 N N 
2-Ethoxybenzamide Phenol 4:1 10:1 132 -37.91 N N 
Indomethacin Phenol 3:1 10:1 311 -22.74 N N 
Lamotrigine Phenol 5:1 10:1 216 22.34 Y N 
Harmine Phenol 4:1 10:1 321 13.49 N Y 
* - Described as HBD:API ratio  † - Of the ubiquitous polymorph Ep - Ratio of eutectic point 
 
Table 1. Summary of API DES properties. 
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Fig. S1 - Powder X-Ray diffraction pattern showing a mixture of benzamide form III (circles) and form I (squares). 
All peaks can be indexed to the form I polymorph of benzamide (CCDC Identifier - BZAMID) and the form III 
polymorph of benzamide (CCDC Identifier – BZAMID08) 
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Fig. S2 - Powder X-Ray diffraction pattern of an aged DXS of ratio 9:1 phenol:benzamide. All peaks can be indexed 
to the form III polymorph of benzamide (CCDC Identifier – BZAMID08). 
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n – no crystallization/melting events observed. n/a – composition not generated/assessed. 
 
Table S1 - Summary table of melting points from DSC results. 
 
 
 
 
 
  
Composition        
 Paracetamol Metacetamol Benzamide 2-Methoxy 
benzamide 
2-Ethoxy 
benzamide 
Metaxalone CBZ 
1:1 -6 16 14 n 22 n/a n/a 
2:1 -6 25 15 n 13 n/a n/a 
3:1 0 19 -6 n n n n 
4:1 10 2 4 -16 5 n n 
5:1 2 29 2 -19 -9 13 n 
6:1 7 25 0 -5 -5 6 n 
7:1 0 29 6 -3 -7 2 -1 
8:1 0 3 2 -9 -1 -3 -1 
9:1 0 15 ? 1 15 10 -10 
10:1 3 25 1 -5 Two 
potential 
melts at ~ 
-1 and 17° 
C 
-1 -4 
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Fig. S3 - Powder X-Ray diffraction pattern of paracetamol. All peaks can be indexed to form II 
of paracetamol (CCDC Identifier - HXACAN). 
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a) 
 
 
 
b) 
 
 
 
 
Fig. S4 - Powder X-ray diffraction patterns of a) paracetamol form I (deep eutomic ratios 4:1 - 
6:1) and b) paracetamol form II (deep eutomic ratios 7:1 - 9:1). All peaks can be indexed to their 
respective polymorph (form I CCDC Identifier – HXACAN01; form II CCDC Identifier - 
HXACAN). 
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Fig. S5 - Powder X-ray diffraction pattern of metacetamol. All peaks can be indexed to form I of 
metacetamol (CCDC Identifier - MENSEE). 
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a) 
 
b) 
 
 
 
 
Fig. S6 - Single crystal X-ray diffraction generated unit cells of a) ethoxybenzamide phenolate 
and b) harmine phenolate (CCDC deposit numbers 1879689 and 1879336, respectively). 
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(a) 
 
 
(b) 
 
 
 
Fig. S7 - Dissolution data for APIs synthesized via a DXS for (a) Carbamazepine and (b) 
Metaxalone. In (a), black squares represent the as-received carbamazepine and blue triangles 
represent the DXS-grown carbamazepine. In (b), black squares represent the as-received 
metaxalone, red circles represent form A of metaxalone grown from a DXS and blue triangles 
represent form C of metaxalone grown from a DXS. 
